Asgard Therapeutics’ study published in Science showing proof-of-concept and strong anti-tumor responses via in vivo cell reprogramming with lead program AT-108
Study of Asgard’s new cancer immunotherapy modality demonstrates potent anti-tumor effects by turning tumor cells against themselves New data “paves the way for first-in-human trials” of lead program AT-108, which is undergoing CMC development for GMP manufacturing AT-108 is an off-the-shelf gene therapy that induces an immune response tailored against each unique patient’s cancer Lund, […]